Teacher Retirement System of Texas Sells 12,028 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

Teacher Retirement System of Texas lessened its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 10.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 103,364 shares of the biopharmaceutical company's stock after selling 12,028 shares during the quarter. Teacher Retirement System of Texas' holdings in Royalty Pharma were worth $3,218,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Nissay Asset Management Corp Japan ADV lifted its stake in shares of Royalty Pharma by 0.7% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock valued at $1,238,000 after acquiring an additional 349 shares during the period. National Bank of Canada FI grew its holdings in Royalty Pharma by 21.8% during the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 371 shares during the period. Sherbrooke Park Advisers LLC grew its holdings in Royalty Pharma by 1.1% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after purchasing an additional 380 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 414 shares during the period. Finally, Hillsdale Investment Management Inc. grew its holdings in Royalty Pharma by 2.5% during the fourth quarter. Hillsdale Investment Management Inc. now owns 24,250 shares of the biopharmaceutical company's stock valued at $619,000 after purchasing an additional 600 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Up 0.7%

Shares of Royalty Pharma stock traded up $0.25 on Thursday, hitting $36.12. The company had a trading volume of 2,335,719 shares, compared to its average volume of 3,707,550. The firm has a market capitalization of $20.31 billion, a P/E ratio of 19.52, a P/E/G ratio of 1.84 and a beta of 0.50. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $36.56. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56. The stock has a 50-day moving average of $34.06 and a 200-day moving average of $32.16.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The business had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. Research analysts predict that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date was Friday, May 16th. Royalty Pharma's dividend payout ratio is presently 47.57%.

Wall Street Analyst Weigh In

RPRX has been the subject of a number of analyst reports. Wall Street Zen cut shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Morgan Stanley set a $54.00 price target on shares of Royalty Pharma and gave the company an "overweight" rating in a report on Thursday. Finally, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $48.33.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.